DOCSLIB.ORG

Mouse Limch1 Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Limch1 Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Limch1 Knockout Project (CRISPR/Cas9) Objective: To create a Limch1 knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Limch1 gene (NCBI Reference Sequence: NM_001001980 ; Ensembl: ENSMUSG00000037736 ) is located on Mouse chromosome 5. 26 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 26 (Transcript: ENSMUST00000101164). Exon 5~7 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 5 starts from about 10.88% of the coding region. Exon 5~7 covers 10.66% of the coding region. The size of effective KO region: ~9684 bp. The KO region does not have any other known gene. Page 1 of 10 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 5 6 7 26 Legends Exon of mouse Limch1 Knockout region Page 2 of 10 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 5 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section downstream of Exon 7 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Page 3 of 10 https://www.alphaknockout.com Overview of the GC Content Distribution (up) Window size: 300 bp Sequence 12 Summary: Full Length(2000bp) | A(27.5% 550) | C(18.55% 371) | T(32.7% 654) | G(21.25% 425) Note: The 2000 bp section upstream of Exon 5 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution (down) Window size: 300 bp Sequence 12 Summary: Full Length(2000bp) | A(25.45% 509) | C(20.1% 402) | T(33.15% 663) | G(21.3% 426) Note: The 2000 bp section downstream of Exon 7 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 4 of 10 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 2000 1 2000 2000 100.0% chr5 + 66957589 66959588 2000 browser details YourSeq 129 1696 1916 2000 92.7% chr1 + 181883559 181883802 244 browser details YourSeq 128 1677 1848 2000 86.0% chr7 - 142047299 142047452 154 browser details YourSeq 124 1515 1848 2000 93.2% chr8 - 22795859 22796426 568 browser details YourSeq 121 1683 1848 2000 85.6% chr13 - 100691239 100691392 154 browser details YourSeq 120 1677 1848 2000 84.9% chr2 + 25004726 25004878 153 browser details YourSeq 119 1718 1990 2000 89.2% chr8 - 93712420 93712691 272 browser details YourSeq 119 1685 1848 2000 92.2% chr6 - 35072686 35073236 551 browser details YourSeq 119 1679 1848 2000 85.9% chr3 - 133565314 133565465 152 browser details YourSeq 119 1693 1848 2000 91.0% chr19 - 7499212 7499504 293 browser details YourSeq 119 1718 1848 2000 96.2% chr19 + 5163673 5164126 454 browser details YourSeq 118 1682 1848 2000 87.0% chr4 - 150987215 150987377 163 browser details YourSeq 118 1645 1847 2000 92.8% chr4 - 106355300 106355751 452 browser details YourSeq 118 1703 1848 2000 88.9% chrX + 144166551 144166689 139 browser details YourSeq 118 1684 1848 2000 85.5% chr11 + 29578426 29578566 141 browser details YourSeq 117 1718 1848 2000 94.7% chr17 + 66459821 66459951 131 browser details YourSeq 117 1718 1854 2000 93.4% chr17 + 45620860 45621005 146 browser details YourSeq 116 1720 1847 2000 95.4% chr2 + 157319058 157319185 128 browser details YourSeq 115 1719 1848 2000 94.7% chr3 - 68831869 68832006 138 browser details YourSeq 115 1698 1848 2000 84.9% chr10 + 4506552 4506690 139 Note: The 2000 bp section upstream of Exon 5 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 2000 1 2000 2000 100.0% chr5 + 66969273 66971272 2000 browser details YourSeq 36 1510 1691 2000 94.9% chr16 - 52763045 52763326 282 browser details YourSeq 34 982 1034 2000 92.5% chr9 - 43881350 43881403 54 browser details YourSeq 31 987 1035 2000 81.7% chr14 - 69799410 69799458 49 browser details YourSeq 31 978 1038 2000 89.5% chr5 + 136283210 136283270 61 browser details YourSeq 30 1240 1283 2000 96.9% chr4 + 25238456 25238871 416 browser details YourSeq 27 987 1031 2000 80.0% chrX - 166521895 166521939 45 browser details YourSeq 26 934 961 2000 96.5% chr9 - 11780936 11780963 28 browser details YourSeq 25 1019 1043 2000 100.0% chr7 + 79333267 79333291 25 browser details YourSeq 24 1014 1039 2000 96.2% chr16 - 93289566 93289591 26 browser details YourSeq 24 1019 1042 2000 100.0% chr13 - 34570179 34570202 24 browser details YourSeq 24 1016 1039 2000 100.0% chr11 - 87674873 87674896 24 browser details YourSeq 24 1019 1042 2000 100.0% chr4 + 57071563 57071586 24 browser details YourSeq 23 985 1031 2000 69.6% chr13 - 14706885 14706930 46 browser details YourSeq 23 801 823 2000 100.0% chr12 - 90146785 90146807 23 browser details YourSeq 23 1016 1038 2000 100.0% chr2 + 63057531 63057553 23 browser details YourSeq 22 1019 1042 2000 95.9% chr3 - 53499384 53499407 24 browser details YourSeq 22 1674 1697 2000 87.0% chr3 - 32663219 32663241 23 browser details YourSeq 21 1019 1039 2000 100.0% chr11 - 100324861 100324881 21 browser details YourSeq 21 1012 1032 2000 100.0% chr1 - 157374501 157374521 21 Note: The 2000 bp section downstream of Exon 7 is BLAT searched against the genome. No significant similarity is found. Page 5 of 10 https://www.alphaknockout.com Gene and protein information: Limch1 LIM and calponin homology domains 1 [ Mus musculus (house mouse) ] Gene ID: 77569, updated on 24-Oct-2019 Gene summary Official Symbol Limch1 provided by MGI Official Full Name LIM and calponin homology domains 1 provided by MGI Primary source MGI:MGI:1924819 See related Ensembl:ENSMUSG00000037736 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as mKIAA1102; 3732412D22Rik Expression Biased expression in lung adult (RPKM 20.3), heart adult (RPKM 7.0) and 11 other tissues See more Orthologs human all Genomic context Location: 5; 5 C3.1 See Limch1 in Genome Data Viewer Exon count: 28 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 5 NC_000071.6 (66745889..67057159) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 5 NC_000071.5 (67137079..67448398) Chromosome 5 - NC_000071.6 Page 6 of 10 https://www.alphaknockout.com Transcript information: This gene has 20 transcripts Gene: Limch1 ENSMUSG00000037736 Description LIM and calponin homology domains 1 [Source:MGI Symbol;Acc:MGI:1924819] Gene Synonyms 3732412D22Rik Location Chromosome 5: 66,745,827-67,057,158 forward strand. GRCm38:CM000998.2 About this gene This gene has 20 transcripts (splice variants), 222 orthologues, 1 paralogue, is a member of 1 Ensembl protein family and is associated with 2 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Limch1- ENSMUST00000038188.13 5903 901aa ENSMUSP00000043163.7 Protein coding CCDS57347 Q3UH68 TSL:1 201 GENCODE basic Limch1- ENSMUST00000101164.10 5192 1057aa ENSMUSP00000098723.4 Protein coding CCDS39102 Q3UH68 TSL:5 202 GENCODE basic APPRIS P2 Limch1- ENSMUST00000238785.1 7498 1511aa ENSMUSP00000158661.1 Protein coding - - GENCODE 219 basic APPRIS ALT2 Limch1- ENSMUST00000238993.1 5981 927aa ENSMUSP00000159044.1 Protein coding - - GENCODE 220 basic Limch1- ENSMUST00000118242.7 5050 1068aa ENSMUSP00000112732.1 Protein coding - D3YU22 TSL:5 204 GENCODE basic APPRIS ALT2 Limch1- ENSMUST00000119854.7 4185 774aa ENSMUSP00000112651.2 Protein coding - D3YU59 CDS 5' 205 incomplete TSL:1 Limch1- ENSMUST00000117601.7 3157 898aa ENSMUSP00000113544.2 Protein coding - D3Z589 TSL:5 203 GENCODE basic Limch1- ENSMUST00000132991.4 876 268aa ENSMUSP00000123337.2 Protein coding - F6X3N8 CDS 3' 209 incomplete TSL:2 Limch1- ENSMUST00000127184.7 852 237aa ENSMUSP00000114681.1 Protein coding - D3YV55 CDS 3' 207 incomplete TSL:5 Limch1- ENSMUST00000122812.4 520 29aa ENSMUSP00000144176.1 Protein coding - A0A0J9YUH0 CDS 3' 206 incomplete TSL:3 Limch1- ENSMUST00000153174.1 435 60aa ENSMUSP00000118979.1 Nonsense mediated - F6W1Y9 CDS 5' 214 decay incomplete TSL:2 Limch1- ENSMUST00000130228.1 360 83aa ENSMUSP00000116126.1 Nonsense mediated - D6RHT2 TSL:5 208 decay Limch1- ENSMUST00000202830.1 2538 No - Retained intron - - TSL:NA 218 protein Limch1- ENSMUST00000140428.7 2458 No - Retained intron - - TSL:1 212 protein Limch1- ENSMUST00000201852.3 1018 No - Retained intron - - TSL:3 216 protein Page 7 of 10 https://www.alphaknockout.com Limch1- ENSMUST00000202048.1 786 No
Load more

Recommended publications
  • WO 2014/135655 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/135655 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2014/054384 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 6 March 2014 (06.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13305253.0 6 March 2013 (06.03.2013) EP (84) Designated States (unless otherwise indicated, for every (71) Applicants: INSTITUT CURIE [FR/FR]; 26 rue d'Ulm, kind of regional protection available): ARIPO (BW, GH, F-75248 Paris cedex 05 (FR). CENTRE NATIONAL DE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3 rue UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Michel Ange, F-75016 Paris (FR).
    [Show full text]
  • Bioinformatics Approaches to Identify Pain Mediators, Novel Lncrnas and Distinct Modalities of Neuropathic Pain
    Bioinformatics approaches to identify pain mediators, novel LncRNAs and distinct modalities of neuropathic pain by Georgios Baskozos A thesis submitted to University College London for the degree of Doctor of Philosophy Institute of Structural and Molecular Biology University College London September 2016 1 Declaration I, Georgios Baskozos, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. ……………………………………… Georgios Baskozos 29 September 2016 2 Abstract This thesis presents a number of studies in the general subject of bioinformatics and functional genomics. The studies were made in collaboration with experimental scientists of the London Pain Consortium (LPC), an initiative that has promoted collaborations between experimental and computational scientists to further understanding of pain. The studies are mainly concerned with the molecular biology of pain and deal with data gathered from high throughput technologies aiming to assess the transcriptional changes involved in well induced pain states, both from animal models of pain and human patients. We have analysed next generation sequencing data (NGS data) in order to assess the transcriptional changes in rodent’s dorsal root ganglions under well induced pain states. We have also developed a customised computational pipeline to analyse RNA- sequencing data in order to identify novel Long non-coding RNAs (LncRNAs), which may function as mediators of neuropathic pain. Our analyses detected hundreds of novel LncRNAs significantly dysregulated between sham-operated animals and animal models of pain. In addition, in order to gain valuable insights into neuropathic pain, including both its molecular signature, somatosensory profiles and clusters of individuals related to pain severity, we analysed clinical data together with data obtained from quality of life pain-questionnaires.
    [Show full text]
  • Chip-Seq Annotation and Visualization How to Add Biological Meaning to Peaks
    ChIP-seq Annotation and Visualization How to add biological meaning to peaks M. Defrance, C. Herrmann, D. Puthier, M. Thomas-Chollier, S Le Gras, J van Helden Our data in the context Custom track uploded by the user (here ESR1 peaks in siGATA3 context) public UCSC annotation/data tracks Typical questions - What are the genes associated to the peaks? ChIP-seq peaks - Are some genomic categories over-represented? - Are some functional categories over-represented? - Are the peaks close to the TSS, …? ChIP-seq peaks Annotation Visualisation Enrichment profiles Annotated peaks Genomic & functional Average Profile near TSS Average Profile near TTS Annotation Genomic location Relation to CpG island 0.30 1.0 2500 0.8 chr start end Gene 0.25 chr15 65294195 65295186 0.6 chrX 19635923 19638359 Chst7 Average Profile Average Profile Average 3000 chr8 33993863 33995559 1500 0.4 0.20 chr10 114236977 114239326 Trhde # of regions # of regions 0.2 Distribution of Peak Heights chrX 69515082 69516482 Gabre 500 chr4 49857142 49858913 Grin3a 1000 −3000 −2000 −1000 0 1000 2000 3000 −3000 −2000 −1000 0 1000 2000 3000 0 5 10 15 chr16 7352861 7353410 Rbfox1 0 0 Relative Distance to TSS (bp) Relative Distance to TTS (bp) chr7 64764156 64765421 Gabra5 ChIP Regions (Peaks) over Chromosomes Average Gene Profile chrX 83436881 83438330 Nr0b1 CGI Shore Distant chr10 120288598 120289143 Msrb3 Multiple 1 Promoter Intergenic 2 chr5 67446361 67446855 Limch1 Gene Body 3 0.8 4 5 6 7 0.6 8 9 Average Profile Average 10 0.4 11 12 Chromosome 13 0.2 14 15 −1000 0 1000 2000 3000 4000 16 Upstream (bp), 3000 bp of Meta−gene, Downstream (bp) 17 18 19 Average Concatenated Exon Profile Average Concatenated Intron Profile X Y 0.0e+00 5.0e+07 1.0e+08 1.5e+08 2.0e+08 1.0 Chromosome Size (bp) 1.0 0.8 0.8 0.6 0.6 Average Profile Average Profile Average 0.4 0.4 0.2 0.2 0 20 40 60 80 100 0 20 40 60 80 100 Relative Location (%) Relative Location (%) Distribution of Peak Heights 0 5 10 15 ChIP Regions (Peaks) over Chromosomes 1 2 3 4 5 6 7 8 9 10 11 12 Chromosome W.Huang et al.
    [Show full text]
  • Supplementary Information For
    Supplementary Information for Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models. Ariadna Bargiela, Maria Sabater-Arcis, Jorge Espinosa-Espinosa, Miren Zulaica, Adolfo Lopez de Munain and Ruben Artero. Corresponding author: Ruben Artero Email: [email protected] This PDF file includes: Supplementary text Figs. S1 to S13 Tables S1 References for SI reference citations 1 www.pnas.org/cgi/doi/10.1073/pnas.1820297116 Supplementary Information Text Materials and methods. Fly strains and crosses w1118 line was obtained from the Bloomington Drosophila Stock Center (Indiana University, Bloomington, IN, USA). Mhc-Gal4 flies were described in (1). Mhc-Gal4 UAS-(CTG)480 flies were generated in (2). All crosses were carried out at 25 °C with standard fly food. For oral administration of chloroquine (Chloroquine diphosphate salt solid, ≥98%, C6628 Sigma Aldrich), a maximum of 25 one-day adult flies were collected in tubes containing standard food supplemented with chloroquine (10 or 100 μM). Flies were transferred to tubes containing fresh food every 2-3 days for a total administration time of 7 days. Determination of caspase-3 and caspase-7 activity Ten adult female flies of the indicated genotypes were homogenized in 100 μl of cold PBS buffer using TissueLyser LT (Qiagen, Hilden, Germany). After a 10 min centrifugation, the supernatant was transferred into a white 96-well plate. Caspase-3 and caspase-7 activity was measured using the Caspase-Glo 3/7 Assay Systems (Promega, Fitchburg, WI, USA). Briefly, 100 μl of Caspase-Glo 3/7 reagent was added per well and the plate was incubated at room temperature for 30 min.
    [Show full text]
  • Microarray and Pattern Miner Analysis of AXL and VIM Gene Networks in MDA‑MB‑231 Cells
    MOLECULAR MEDICINE REPORTS 18: 4147-4155, 2018 Microarray and pattern miner analysis of AXL and VIM gene networks in MDA‑MB‑231 cells SUDHAKAR NATARAJAN1, VENIL N SUMANTRAN2, MOHAN RANGANATHAN1 and SURESH MADHESWARAN1 1Department of Biotechnology, Faculty of Engineering and Technology; 2Dr. A.P.J. Abdul Kalam Centre for Excellence in Innovation and Entrepreneurship, Dr. M.G.R. Educational and Research Institute, Tamil Nadu, Chennai 600095, India Received March 20, 2018; Accepted August 2, 2018 DOI: 10.3892/mmr.2018.9404 Abstract. MDA-MB-231 cells represent malignant triple-nega- migration, metastasis and chemoresistance, whereas the VIM tive breast cancer, which overexpress epidermal growth factor gene network regulates novel tumorigenic processes, such as receptor (EGFR) and two genes (AXL and VIM) associated lipogenesis, senescence and autophagy. Notably, these two with poor prognosis. The present study aimed to identify novel networks contain 12 genes not reported for TNBC. therapeutic targets and elucidate the functional networks for the AXL and VIM genes in MDA-MB-231 cells. We identi- Introduction fied 71 genes upregulated in MDA-MB-231 vs. MCF7 cells using BRB-Array tool to re-analyse microarray data from six Triple negative breast cancers (TNBC) lack expression of three GEO datasets. Gene ontology and STRING analysis showed important receptors (ER, PR, and HER2). These cancers account that 43/71 genes upregulated in MDA-MB-231 compared with for 10-15% of breast cancers, and are characterized by overex- MCF7 cells, regulate cell survival and migration. Another pression of epidermal growth factor receptor (EGFR), high 19 novel genes regulate migration, metastases, senescence, proliferative rate, and mutations in the p53 and BRCA1 tumour autophagy and chemoresistance.
    [Show full text]
  • A Genome-Wide Linkage and Association Study of Musical Aptitude Identifies Loci Containing Genes Related to Inner Ear Development and Neurocognitive Functions
    Molecular Psychiatry (2015) 20, 275–282 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp ORIGINAL ARTICLE A genome-wide linkage and association study of musical aptitude identifies loci containing genes related to inner ear development and neurocognitive functions J Oikkonen1,2, Y Huang3, P Onkamo2, L Ukkola-Vuoti1, P Raijas4, K Karma4, VJ Vieland3 and I Järvelä1 Humans have developed the perception, production and processing of sounds into the art of music. A genetic contribution to these skills of musical aptitude has long been suggested. We performed a genome-wide scan in 76 pedigrees (767 individuals) characterized for the ability to discriminate pitch (SP), duration (ST) and sound patterns (KMT), which are primary capacities for music perception. Using the Bayesian linkage and association approach implemented in program package KELVIN, especially designed for complex pedigrees, several single nucleotide polymorphisms (SNPs) near genes affecting the functions of the auditory pathway and neurocognitive processes were identified. The strongest association was found at 3q21.3 (rs9854612) with combined SP, ST and KMT test scores (COMB). This region is located a few dozen kilobases upstream of the GATA binding protein 2 (GATA2) gene. GATA2 regulates the development of cochlear hair cells and the inferior colliculus (IC), which are important in tonotopic mapping. The highest probability of linkage was obtained for phenotype SP at 4p14, located next to the region harboring the protocadherin 7 gene, PCDH7. Two SNPs rs13146789 and rs13109270 of PCDH7 showed strong association. PCDH7 has been suggested to play a role in cochlear and amygdaloid complexes. Functional class analysis showed that inner ear and schizophrenia- related genes were enriched inside the linked regions.
    [Show full text]
  • Induced Pluripotent Stem Cells from Subjects with Lesch-Nyhan Disease
    www.nature.com/scientificreports OPEN Induced pluripotent stem cells from subjects with Lesch‑Nyhan disease Diane J. Sutclife1,12, Ashok R. Dinasarapu2,12, Jasper E. Visser3,4, Joery den Hoed1, Fatemeh Seifar1,5, Piyush Joshi1, Irene Ceballos‑Picot6, Tejas Sardar1, Ellen J. Hess1,5,7, Yan V. Sun8, Zhexing Wen1,9,10, Michael E. Zwick2,11 & H. A. Jinnah1,2,5,11* Lesch‑Nyhan disease (LND) is an inherited disorder caused by pathogenic variants in the HPRT1 gene, which encodes the purine recycling enzyme hypoxanthine–guanine phosphoribosyltransferase (HGprt). We generated 6 induced pluripotent stem cell (iPSC) lines from 3 individuals with LND, along with 6 control lines from 3 normal individuals. All 12 lines had the characteristics of pluripotent stem cells, as assessed by immunostaining for pluripotency markers, expression of pluripotency genes, and diferentiation into the 3 primary germ cell layers. Gene expression profling with RNAseq demonstrated signifcant heterogeneity among the lines. Despite this heterogeneity, several anticipated abnormalities were readily detectable across all LND lines, including reduced HPRT1 mRNA. Several unexpected abnormalities were also consistently detectable across the LND lines, including decreases in FAR2P1 and increases in RNF39. Shotgun proteomics also demonstrated several expected abnormalities in the LND lines, such as absence of HGprt protein. The proteomics study also revealed several unexpected abnormalities across the LND lines, including increases in GNAO1 decreases in NSE4A. There was a good but partial correlation between abnormalities revealed by the RNAseq and proteomics methods. Finally, functional studies demonstrated LND lines had no HGprt enzyme activity and resistance to the toxic pro‑drug 6‑thioguanine.
    [Show full text]
  • Whole-Exome Sequencing to Identify Potential Genetic Risk in Substance Use Disorders: a Pilot Feasibility Study
    Journal of Clinical Medicine Brief Report Whole-Exome Sequencing to Identify Potential Genetic Risk in Substance Use Disorders: A Pilot Feasibility Study P. V. AshaRani 1 , Syidda Amron 2, Noor Azizah Bte Zainuldin 2, Sumanty Tohari 3, Alvin Y. J. Ng 3, Guo Song 2, Byrappa Venkatesh 3,4,* and Ajay S. Mathuru 3,5,6,* 1 Research Division, Institute of Mental Health, Singapore 539747, Singapore; [email protected] 2 National Addictions Management Service, Institute of Mental Health, Singapore 539747, Singapore; [email protected] (S.A.); [email protected] (N.A.B.Z.); [email protected] (G.S.) 3 Institute of Molecular and Cell Biology, Singapore 138673, Singapore; [email protected] (S.T.); [email protected] (A.Y.J.N.) 4 Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore 5 Yale-NUS College, Singapore 138610, Singapore 6 Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117593, Singapore * Correspondence: [email protected] (B.V.); [email protected] (A.S.M.) Abstract: Genetics intersects with environmental, cultural, and social factors in the development of addictive disorders. This study reports the feasibility of whole-exome sequencing of trios (subject and two family members) to discover potential genetic variants in the development of substance use disorders (SUD). Family trios were recruited from the National Addictions Management Service in Citation: AshaRani, P.V.; Amron, S.; Singapore during the 2016–2018 period. Recruited subjects had severe alcohol use disorder (AUD) Zainuldin, N.A.B.; Tohari, S.; Ng, or opioid use disorder (OUD), with nicotine dependence (ND) and a family history of addictive A.Y.J.; Song, G.; Venkatesh, B.; disorders.
    [Show full text]
  • Content Based Search in Gene Expression Databases and a Meta-Analysis of Host Responses to Infection
    Content Based Search in Gene Expression Databases and a Meta-analysis of Host Responses to Infection A Thesis Submitted to the Faculty of Drexel University by Francis X. Bell in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2015 c Copyright 2015 Francis X. Bell. All Rights Reserved. ii Acknowledgments I would like to acknowledge and thank my advisor, Dr. Ahmet Sacan. Without his advice, support, and patience I would not have been able to accomplish all that I have. I would also like to thank my committee members and the Biomed Faculty that have guided me. I would like to give a special thanks for the members of the bioinformatics lab, in particular the members of the Sacan lab: Rehman Qureshi, Daisy Heng Yang, April Chunyu Zhao, and Yiqian Zhou. Thank you for creating a pleasant and friendly environment in the lab. I give the members of my family my sincerest gratitude for all that they have done for me. I cannot begin to repay my parents for their sacrifices. I am eternally grateful for everything they have done. The support of my sisters and their encouragement gave me the strength to persevere to the end. iii Table of Contents LIST OF TABLES.......................................................................... vii LIST OF FIGURES ........................................................................ xiv ABSTRACT ................................................................................ xvii 1. A BRIEF INTRODUCTION TO GENE EXPRESSION............................. 1 1.1 Central Dogma of Molecular Biology........................................... 1 1.1.1 Basic Transfers .......................................................... 1 1.1.2 Uncommon Transfers ................................................... 3 1.2 Gene Expression ................................................................. 4 1.2.1 Estimating Gene Expression ............................................ 4 1.2.2 DNA Microarrays ......................................................
    [Show full text]
  • LIMCH1 Rabbit Polyclonal Antibody – TA308060 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA308060 LIMCH1 Rabbit Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: IHC, WB Recommended Dilution: IHC:1:100-1:1000; WB:1:500-1:3000 Reactivity: Human, Mouse (Predicted: Xenopus, Zebrafish, Cow) Host: Rabbit Isotype: IgG Clonality: Polyclonal Immunogen: Recombinant fragment contain a sequence corresponding to a region within amino acids 734 and 1007 of LIMCH1 (Uniprot ID#Q9UPQ0) Formulation: 1XPBS, 20% Glycerol (pH7). 0.025% ProClin 300 was added as a preservative. Concentration: lot specific Purification: Purified by antigen-affinity chromatography. Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 119 kDa Gene Name: LIM and calponin homology domains 1 Database Link: NP_001106191 Entrez Gene 77569 MouseEntrez Gene 22998 Human Q9UPQ0 Synonyms: LIMCH1A; LMO7B Note: Seq homology of immunogen across species: Cow (87%), Zebrafish (45%), Xenopus laevis (84%) This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 LIMCH1 Rabbit Polyclonal Antibody – TA308060 Product images: Sample (30ug whole cell lysate). A:H1299. 7.5% SDS PAGE. TA308060 diluted at 1:3000 Sample (50 ug of whole cell lysate). A: Mouse brain. 5% SDS PAGE. TA308060 diluted at 1:2000. This product is to be used for laboratory only. Not for diagnostic or therapeutic use.
    [Show full text]
  • Weighted Cox Regression for the Prediction of Heterogeneous Patient
    WEIGHTED COX REGRESSION FOR THE PREDICTION OF HETEROGENEOUS PATIENT SUBGROUPS Katrin Madjar Jörg Rahnenführer Department of Statistics Department of Statistics TU Dortmund University TU Dortmund University 44221 Dortmund, Germany 44221 Dortmund, Germany [email protected] [email protected] March 23, 2020 ABSTRACT An important task in clinical medicine is the construction of risk prediction models for specific subgroups of patients based on high-dimensional molecular measurements such as gene expression data. Major objectives in modeling high-dimensional data are good prediction performance and feature selection to find a subset of predictors that are truly associated with a clinical outcome such as a time-to-event endpoint. In clinical practice, this task is challenging since patient cohorts are typically small and can be heterogeneous with regard to their relationship between predictors and outcome. When data of several subgroups of patients with the same or similar disease are available, it is tempting to combine them to increase sample size, such as in multicenter studies. However, heterogeneity between subgroups can lead to biased results and subgroup-specific effects may remain undetected. For this situation, we propose a penalized Cox regression model with a weighted version of the Cox partial likelihood that includes patients of all subgroups but assigns them individual weights based on their subgroup affiliation. Patients who are likely to belong to the subgroup of interest obtain higher weights in the subgroup-specific model. Our proposed approach is evaluated through simulations and application to real lung cancer cohorts. Simulation results demonstrate that our model can achieve improved prediction and variable selection accuracy over standard approaches.
    [Show full text]
  • WO 2014/028907 Al 20 February 2014 (20.02.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/028907 Al 20 February 2014 (20.02.2014) P O P C T (51) International Patent Classification: (74) Agents: EVANS, Judith et al; P.O. Box 23 1, Manassas, C12Q 1/68 (2006.01) G01N 33/00 (2006.01) VA 20108 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 13/055469 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 16 August 2013 (16.08.2013) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 61/684,029 16 August 2012 (16.08.2012) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 61/718,468 25 October 2012 (25. 10.2012) US TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 61/745,207 2 1 December 2012 (21. 12.2012) US ZW. (71) Applicant: THE TRUSTEES OF COLUMBIA UNI¬ (84) Designated States (unless otherwise indicated, for every VERSITY IN THE CITY OF NEW YORK [US/US]; kind of regional protection available): ARIPO (BW, GH, 412 Low Memorial Library, 535 West 116th Street, New GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, York, NY 10027 (US).
    [Show full text]